Privia Health (PRVA) Q2 2026 earnings review
Operating Leverage Shines While Cash Flow Lags
Privia Health delivered a strong Q2, growing Revenue 21.4% YoY to $632.6M and expanding Adjusted EBITDA by 29.1% to $37.4M. The company's shared-risk, fee-based model successfully insulates it from the Medicare Advantage and elevated utilization headwinds currently crushing full-risk peers. However, a massive spike in Accounts Receivable pushed first-half Operating Cash Flow into negative territory (-$48.4M) despite GAAP earnings growth. Management raised the floor on Attributed Lives guidance and expects to hit the high end of their FY26 financial targets, signaling clear visibility into the second half.
🐂 Bull Case
EBITDA consistently outpaces top-line growth. Platform Contribution Margin expanded to 52.2% from 49.9% a year ago, proving the core technology stack scales highly efficiently as new providers are added.
Privia holds $412.2M in cash with zero debt. In a fragmented market where PE-backed competitors are struggling with funding, Privia is uniquely positioned to consolidate at distressed valuations.
🐻 Bear Case
First-half Operating Cash Flow dropped to -$48.4M while Net Income grew 75%. A $172.4M build-up in Accounts Receivable means actual cash generation is heavily back-half weighted and dependent on CMS payouts.
GAAP Net Income of $9.0M is heavily propped up by adjustments. Q2 included $19.4M in stock-based compensation, which equates to an outsized 52% of Adjusted EBITDA.
⚖️ Verdict: 🟢
Bullish. The shared-risk model proves superior in the current macro environment. The AR spike requires a watchful eye, but the structural margin expansion and robust provider volume growth justify a premium valuation.
Key Themes
Provider & Attributed Life Growth
The core volume engine remains strong. Implemented Providers grew 10.1% YoY to 5,644, while Value-Based Care Attributed Lives surged 19.2% to 1.647M. This organic momentum naturally feeds the higher-margin shared savings and care management fee lines.
Shared-Risk Model Defies Macro Headwinds
Unlike capitated peers suffering from elevated healthcare utilization and Medicare Advantage V28 rate pressures, Privia's hybrid model thrives. Elevated utilization directly drives their Fee-for-Service patient care revenue (up 25% YoY to $412.6M), while their upside-heavy shared risk contracts protect the bottom line from severe medical cost blowouts.
AI as the Next Margin Catalyst
Management continues to position AI as the primary vehicle to push EBITDA-to-Care-Margin above their 30-35% long-term target. Tools like Navina for clinical point-of-care decisions and automated RCM systems are targeted at reducing physician administrative burden by 10-20%.
Red Flag: Receivables Spike Crushes Cash Flow
Operating Cash Flow moved violently opposite to Net Income in H1. While GAAP Net Income grew 75%, Net Cash Used in Operating Activities worsened to -$48.4M from -$16.1M a year ago. The culprit is a massive $172.4M increase in Accounts Receivable. While this is likely a timing issue related to delayed MSSP settlement payouts, it temporarily weakens the liquidity profile.
Stock-Based Compensation Inflates Non-GAAP Reality
The gap between actual and adjusted profitability is structural. In Q2, Privia recorded $19.4M in stock compensation expense against just $11.8M in Operating Income. SBC accounts for 76% of the bridge to Adjusted Net Income, meaning true economic margins are substantially lower than headline non-GAAP metrics suggest.
Decelerating Revenue Growth
While impressive, top-line growth is visibly decelerating. Total revenue growth stepped down from 32.5% in 25Q3, to 25.7% in 26Q1, to 21.4% in 26Q2. As the law of large numbers takes effect, Privia must increasingly rely on operating leverage and strategic M&A to sustain its ~20% EBITDA growth target.
Other KPIs
Up 12.4% YoY from $862.9M. This non-GAAP metric captures the total economic value running through Privia's platform, including non-owned medical groups. While robust, its growth trails the 21.4% GAAP revenue growth, reflecting shifts in the mix toward higher-capture value-based arrangements.
Up 14.7% YoY. Care margin growth trailing revenue growth (21.4%) indicates slight gross margin compression (from 21.6% to 20.4%), primarily due to a 23.3% spike in Provider Expense as the network rapidly expands.
Up 26.0% YoY. Though Privia actively avoids full-risk downside, its targeted, strategic capitation book is growing faster than overall revenue, driving higher margin dollars but also increasing unpaid medical claim liabilities, which stood at $98.9M at quarter end.
Guidance
Stable. The company expects to trend toward the 'Mid to High End' of this range. At the $150M midpoint, this implies an accelerating ~19.5% YoY growth over FY25's $125.5M actuals.
Stable. Management noted they expect to hit the 'High End' of this GAAP revenue range. The $2.45B high-end implies ~15.4% YoY growth, marking a deceleration compared to the ~20%+ growth achieved in FY25, reflecting market maturation and base effects.
Accelerating slightly vs prior guidance. The bottom end of the range was raised by 25,000 lives. However, implied YoY growth at the midpoint is only ~6.3%, which marks a severe deceleration from the current 19.2% Q2 YoY growth. This implies a very conservative posture regarding second-half organic additions.
Stable. Expected to track to the 'High End'. At $3.75B, this represents ~8% YoY growth over FY25, indicating that volume growth is normalizing.
Key Questions
Accounts Receivable Build
Accounts receivable spiked by $172M in the first half, driving operating cash flow deeply negative. How much of this is structural due to payer payment delays versus standard timing of expected Q3/Q4 MSSP shared savings payouts?
M&A Pipeline Specifics
With $412M in cash and no debt during a period where PE-backed, full-risk peers are highly distressed, what specific valuation multiples are you currently seeing in the market for potential primary care acquisitions?
Stock-Based Comp Leverage
Stock-based compensation remains over 50% of Adjusted EBITDA. Given the expanding scale of the business, in what year or at what revenue threshold do you expect SBC to meaningfully decline as a percentage of overall revenue?